API Product   :    Sacubitril-Valsartan*
CEP   :    -
WCC   :    -
Therapeutic Use    :    Urologicals; Other cardiovascular products
Originator   :    Novartis
CAS No.    :    936623-90-4
Trade Name.   :    Entresto, Azmarda
Molecular Weight   :    1916.018 g/mol
Molecular Formula   :    C96H120N12Na6O21
Valsartan is an angiotensin II receptor blocker (sometimes called an ARB). Valsartan keeps blood vessels from narrowing, which lowers blood pressure and improves blood flow. Sacubitril and valsartan is a combination medicine used in certain people with chronic heart failure.
Sacubitril/valsartan, sold under the brand name Entresto among others, is a combination drug for use in heart failure developed by Novartis. It consists of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker valsartan, in a 1:1 mixture by molecule count. It is recommended for use as a replacement for an ACE inhibitor or an angiotensin receptor blocker in people with heart failure with reduced ejection fraction.[1] Potential side effects include angioedema, kidney problems, and low blood pressure.[1] The risk of kidney problems and increased levels of serum potassium with sacubitril/valsartan is lower than that of an ACE inhibitor or angiotensin receptor blocker. The combination is sometimes described as an "angiotensin receptor-neprilysin inhibitor".